Trilogy Capital Inc. Acquires New Stake in Humacyte, Inc. (NASDAQ:HUMA)

Trilogy Capital Inc. bought a new position in shares of Humacyte, Inc. (NASDAQ:HUMA) in the 4th quarter, HoldingsChannel.com reports. The institutional investor bought 83,500 shares of the company’s stock, valued at approximately $422,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Brookstone Capital Management acquired a new stake in shares of Humacyte in the fourth quarter valued at about $56,000. ACT Wealth Management LLC acquired a new position in shares of Humacyte in the fourth quarter worth approximately $57,000. Concurrent Investment Advisors LLC bought a new stake in Humacyte in the third quarter valued at approximately $75,000. FORA Capital LLC acquired a new stake in Humacyte during the 3rd quarter valued at approximately $96,000. Finally, Insigneo Advisory Services LLC bought a new position in Humacyte during the 3rd quarter worth approximately $109,000. 44.71% of the stock is owned by institutional investors and hedge funds.

Humacyte Price Performance

Shares of HUMA opened at $4.27 on Friday. Humacyte, Inc. has a one year low of $2.81 and a one year high of $9.97. The company has a market cap of $537.42 million, a PE ratio of -3.19 and a beta of 1.30. The stock has a 50-day moving average of $4.53 and a 200-day moving average of $5.46.

Humacyte (NASDAQ:HUMA) last announced its quarterly earnings data on Friday, November 8th. The company reported ($0.33) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.08). During the same quarter in the previous year, the business earned ($0.25) earnings per share. Analysts expect that Humacyte, Inc. will post -1.27 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. D. Boral Capital reaffirmed a “buy” rating and issued a $25.00 price objective on shares of Humacyte in a research note on Tuesday, January 21st. BTIG Research reaffirmed a “buy” rating and set a $10.00 price target on shares of Humacyte in a research report on Friday, October 18th. Piper Sandler set a $6.00 price objective on Humacyte and gave the stock a “neutral” rating in a research report on Friday, October 18th. Benchmark boosted their price objective on Humacyte from $15.00 to $17.00 and gave the company a “buy” rating in a research note on Monday, December 23rd. Finally, TD Cowen reaffirmed a “buy” rating and set a $10.00 target price on shares of Humacyte in a research note on Friday, October 18th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $13.71.

Insider Transactions at Humacyte

In other news, CEO Laura E. Niklason sold 811,172 shares of Humacyte stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $4.44, for a total transaction of $3,601,603.68. Following the completion of the transaction, the chief executive officer now directly owns 2,419,712 shares in the company, valued at $10,743,521.28. This trade represents a 25.11 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Brady W. Dougan sold 427,459 shares of the company’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $4.34, for a total transaction of $1,855,172.06. Following the completion of the sale, the director now owns 1,992,253 shares in the company, valued at $8,646,378.02. This represents a 17.67 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,500,000 shares of company stock valued at $6,606,799 over the last ninety days. 11.20% of the stock is owned by company insiders.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.